High-performance liquid chromatographic determination of a new oral thrombin inhibitor in the blood of rats and dogs

被引:4
作者
Lee, SH [1 ]
Choi, YJ [1 ]
Jeong, YN [1 ]
Kim, HS [1 ]
Lee, SH [1 ]
Kim, IC [1 ]
Oh, YS [1 ]
Lee, YH [1 ]
机构
[1] LG Chem Biotech Res Inst, Taejon 305380, South Korea
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 1998年 / 714卷 / 02期
关键词
thrombin inhibitors; (S)-N-cyclopentyl-N-methyl-3-(4-amidrazonophenyl)-2-(2-naphtylsulfonylamino)-propionamide;
D O I
10.1016/S0378-4347(98)00200-X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A reliable reversed-phase high-performance liquid chromatographic method has been developed for the determination of a new oral thrombin inhibitor (compound I) in the blood of rats and dogs. The analyte was deproteinized with a 1.5 volume of methanol and a 0.5 volume of 10% zinc sulfate, and the supernatant was injected into a 5-mu m Capcell Pak C-18 column (150x4.6 mm I.D.). The mobile phase was a mixture of acetonitrile and 0.2% triethylamine of pH 2.3 (31:69, v/v) with a flow-rate of 1.0 ml/min at UV 231 nm. The retention time of compound I was approximately 9.3 min. The calibration curve was linear over the concentration range of 0.05-100 mg/l for rat blood (r(2)>0.9995, n=6) and dog blood (r(2)>0.9993, n=6). The limit of quantitation was 0.05 mg/l for both bloods using a 100-mu l sample. For the 5 concentrations (0.05, 0.1, 1, 10, and 100 mg/l), the within-day recovery (n=4) and precision (n=4) were 98.1-104.1% and 1.5-6.8% for rat blood and 95.4-105.7% and 1.4-5.3% for dog blood, respectively. The between-day recovery (n=6) and precision (n=6) were 99.8-105.3% and 3.7-12.6% for rat blood and 87.5-107.1% and 2.9-15.3% for dog blood, respectively. The absolute recoveries were 82.4-93.3%. No interferences from endogenous substances were observed. In conclusion, the presented simple, sensitive, and reproducible HPLC method proved and was used successfully for the determination of compound I in the preclinical pharmacokinetics. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:379 / 383
页数:5
相关论文
共 14 条
[1]  
BADIMON L, 1994, HAEMOSTASIS, V24, P69
[2]  
BAGDY D, 1992, THROMB HAEMOSTASIS, V67, P357
[3]  
Berliner L.J., 1992, THROMBIN STRUCTURE F
[4]  
BRISTOL JA, 1992, ANNU REP MED CHEM, V27, P104
[5]   THROMBIN [J].
FENTON, JW .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES-SERIES, 1986, 485 :5-15
[6]  
KETTNER C, 1990, J BIOL CHEM, V265, P18289
[7]   SELECTIVE-INHIBITION OF THROMBIN BY (2R,4R)-4-METHYL-1-[N2-[(3-METHYL-1,2,3,4-TETRAHYDRO-8-QUINOLINYL)SULFONYL]-L-ARGINYL)]-2-PIPERIDINECARBOXYLIC ACID [J].
KIKUMOTO, R ;
TAMAO, Y ;
TEZUKA, T ;
TONOMURA, S ;
HARA, H ;
NINOMIYA, K ;
HIJIKATA, A ;
OKAMOTO, S .
BIOCHEMISTRY, 1984, 23 (01) :85-90
[8]  
Kim IC, 1997, CIRCULATION, V96, P214
[9]   Rational design of selective thrombin inhibitors [J].
Kim, S ;
Hwang, SY ;
Kim, YK ;
Yun, M ;
Oh, YS .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (07) :769-774
[10]   CHALLENGES IN THE DEVELOPMENT OF ORALLY BIOAVAILABLE THROMBIN ACTIVE-SITE INHIBITORS [J].
KIMBALL, SD .
BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 (06) :511-519